While Allogene Therapeutics Inc has underperformed by -1.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLO fell by -60.14%, with highs and lows ranging from $3.78 to $1.09, whereas the simple moving average fell by -47.21% in the last 200 days.
On March 14, 2025, Citizens JMP Upgraded Allogene Therapeutics Inc (NASDAQ: ALLO) to Mkt Outperform. Piper Sandler also rated ALLO shares as ‘Overweight’, setting a target price of $11 on the company’s shares in an initiating report dated May 31, 2024. Guggenheim January 05, 2024d its ‘Buy’ rating to ‘Neutral’ for ALLO, as published in its report on January 05, 2024. Citigroup’s report from December 08, 2023 suggests a price prediction of $7 for ALLO shares, giving the stock a ‘Buy’ rating. Citigroup also rated the stock as ‘Buy’.
Analysis of Allogene Therapeutics Inc (ALLO)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Allogene Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -55.13% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.54, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 5.56M can be a very valuable indicator of volatility for ALLO stock. On a monthly basis, the volatility of the stock is set at 9.52%, whereas on a weekly basis, it is put at 15.69%, with a loss of -31.76% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.18, showing growth from the present price of $1.16, which can serve as yet another indication of whether ALLO is worth investing in or should be passed over.
How Do You Analyze Allogene Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 34.52%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 64.70% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ALLO shares are owned by institutional investors to the tune of 64.70% at present.
